AFib and Stroke Risk: Could a Clinical Study Help?

Atrial fibrillation, commonly called AFib, is one of the most prevalent heart rhythm disorders in the United States. For many people, it is more than an inconvenient flutter in the chest — it is a significant and often underestimated risk factor for stroke. If you or someone you care about has been diagnosed with AFib, understanding that connection is the first step toward taking it seriously.

What Is Atrial Fibrillation (AFib)?

AFib is a condition in which the heart's upper chambers, called the atria, beat irregularly instead of in a coordinated rhythm. Rather than squeezing in a strong, controlled way to push blood into the lower chambers, the atria quiver rapidly and unpredictably. The result is an irregular and often rapid heartbeat that the heart cannot sustain efficiently over time.

AFib affects millions of Americans and becomes more common with age. Some people experience noticeable symptoms such as palpitations, fatigue, or shortness of breath. Others feel nothing at all and only learn of the condition during a routine checkup or after experiencing a more serious event.

The Stroke Connection: Why AFib Is Dangerous

The irregular rhythm of AFib does not just affect how the heart feels — it changes how blood moves through it. When the atria fibrillate, blood tends to swirl and pool rather than flow smoothly, especially in a small pouch called the left atrial appendage. Blood that sits still rather than circulating can form a clot. If a piece of that clot breaks free and travels to the brain, it blocks an artery and causes a stroke.

People with AFib are several times more likely to have a stroke than those without the condition, and strokes linked to AFib tend to be more severe. The risk is real, persistent, and present even when the heart feels like it is beating normally.

Current Treatment Limitations and Why New Options Matter

The standard approach to reducing stroke risk in AFib is anticoagulation — blood thinners that make clotting less likely. Warfarin was the primary option for decades, and newer direct oral anticoagulants, known as DOACs, have largely replaced it for many patients, offering more predictable results and fewer dietary interactions.

But these medications are not right for everyone. Some patients cannot tolerate standard anticoagulants because of bleeding complications, kidney function concerns, drug interactions, or other medical factors. For those individuals, the standard toolkit falls short — leaving a meaningful stroke risk without an adequate treatment option.

Researchers are actively exploring alternatives. One area of particular interest is a class of investigational treatments that targets Factor XI, a protein involved in clotting. The goal is to reduce clot formation without dramatically increasing bleeding risk — addressing the core problem of AFib-related stroke while potentially being safer for people who could not tolerate earlier options.

What Participating in a Clinical Study Involves

Clinical studies are how new treatments move from laboratory findings to options that doctors can actually offer patients. Participation is voluntary, and every study at Arrow Clinical Trials is conducted under rigorous safety protocols with ongoing monitoring by an experienced clinical team.

For the AFib study at Arrow, participants are randomly assigned to receive either the investigational medication or a placebo. Neither participants nor the study team know which is assigned during the trial — a design standard that keeps results unbiased. All participants continue their regular medical care throughout. Many participants report that the level of attention and monitoring they receive during a study exceeds what a typical office visit provides, and all study-related procedures are covered at no cost.

Who May Qualify for the Arrow AFib Study

The AFib and stroke prevention study at Arrow Clinical Trials in Daytona Beach is evaluating abelacimab, an investigational Factor XI inhibitor administered as a monthly injection, in adults with atrial fibrillation who are considered unsuitable for standard oral anticoagulant therapy.

You may be a candidate if you are 65 or older, have been diagnosed with AFib or atrial flutter, and are not currently able to safely take standard blood thinners. The study research team will conduct a thorough screening process to determine eligibility — no commitment is required to find out whether you qualify.

Enroll in Daytona Beach — No Cost to Participate

Arrow Clinical Trials conducts this research in Daytona Beach, FL, making it accessible to patients across Volusia County and the surrounding area. All study-related care, procedures, and visits are provided at no cost to participants. Compensation for time and travel is also available.

Arrow was founded on the idea of clinical research as a genuine care option — a way to explore tomorrow's treatments today. Every study is managed with accuracy, precision, and follow-through from a team with deep experience in clinical research.

Arrow Clinical Trials is currently enrolling participants for an AFib and stroke prevention study. Participation is free — see if you qualify today.

Frequently Asked Questions

What is an AFib study near me?

An AFib study is a clinical trial evaluating new approaches to treating atrial fibrillation or its complications, such as stroke prevention. Arrow Clinical Trials in Daytona Beach is currently enrolling adults with AFib for a study of an investigational anticoagulant medication.

How does AFib cause strokes?

When the heart fibrillates, blood pools in the upper chambers rather than circulating normally. This pooling can allow a clot to form. If the clot breaks free and travels to the brain, it causes an ischemic stroke. People with AFib face a significantly elevated stroke risk compared to those without the condition.

Who can participate in the Arrow AFib study?

The study is open to adults 65 and older who have been diagnosed with atrial fibrillation or atrial flutter and who cannot safely take standard oral anticoagulants. The research team will screen all applicants to confirm eligibility at no cost and with no obligation.

Is there a cost to participate?

No. All study-related care, tests, and procedures are provided free of charge. Participants may also receive compensation for their time and travel. Health insurance is not required.

What is abelacimab?

Abelacimab is an investigational medication that targets Factor XI, a protein involved in blood clotting. It is being studied as a potential option for stroke prevention in AFib patients who cannot take standard blood thinners. It is administered as a monthly injection and is currently in Phase 3 clinical trials.